+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Nucleic Acid-Based Drugs Market by Drug Type (Antisense Oligonucleotides, DNA/RNA Aptamers, mRNA-Based Therapeutics), Molecule Type (Large Molecule, Small Molecule), Route of Administration, Therapeutic Area, End-User - Global Forecast 2025-2030- Product Image
Nucleic Acid-Based Drugs Market by Drug Type (Antisense Oligonucleotides, DNA/RNA Aptamers, mRNA-Based Therapeutics), Molecule Type (Large Molecule, Small Molecule), Route of Administration, Therapeutic Area, End-User - Global Forecast 2025-2030- Product Image
Sale

Nucleic Acid-Based Drugs Market by Drug Type (Antisense Oligonucleotides, DNA/RNA Aptamers, mRNA-Based Therapeutics), Molecule Type (Large Molecule, Small Molecule), Route of Administration, Therapeutic Area, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 193 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6013698
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The nucleic acid-based drugs market is experiencing rapid transformation, driven by technological innovation, new regulatory frameworks, and increasing therapeutic demand across diverse disease areas. Senior decision-makers seeking a clear competitive edge should understand the market’s evolving dynamics, regional trends, and actionable strategic options to maintain leadership and foster growth.

Market Snapshot: Nucleic Acid-Based Drugs Market Size and Projected Growth

The Nucleic Acid-Based Drugs Market grew from USD 33.37 billion in 2024 to USD 37.76 billion in 2025 and is forecasted to expand at a CAGR of 13.39%, reaching USD 70.95 billion by 2030. Against this market backdrop, senior executives must navigate a landscape shaped by breakthrough RNA and DNA therapeutics, regulatory adaptation, investment momentum, and strong regional ecosystems.

Nucleic Acid-Based Drugs Market Scope & Segmentation

Spanning innovation in therapeutic classes, manufacturing routes, and a diverse end-user base, the market encompasses multiple axes of growth opportunity. Stakeholders are increasingly focused on the deployment of advanced molecular technologies and scalable production methods to serve diverse patient populations and maximize returns across distinct healthcare systems.

  • Drug Types: Antisense oligonucleotides, DNA/RNA aptamers, mRNA-based therapeutics, nucleoside analogs, as well as RNA interference therapeutics such as microRNA, short hairpin RNA, and short interfering RNA agents.
  • Molecule Types: Includes both large biologic molecules requiring specialized manufacturing and small molecules benefiting from established chemical synthesis.
  • Routes of Administration: Inhalation, intramuscular, intravenous, oral, and subcutaneous, enabling tailored therapy based on indication and setting.
  • Therapeutic Areas: Cardiovascular and metabolic disorders, neurological, rare diseases, infectious diseases (bacterial, fungal, viral), and oncology subdivided into hematologic and solid tumors.
  • End-Users: Academic and research institutes, contract research organizations, hospitals and clinics, and pharmaceutical & biotechnology companies.
  • Regions Covered: Americas (including the United States and key states, Canada, Mexico, Brazil, Argentina); Europe, Middle East & Africa (covering major Western, Eastern, and Middle Eastern markets); Asia-Pacific (notably China, India, Japan, Australia, South Korea, and Southeast Asian economies).
  • Key Companies: Market analysis extends to innovators such as Alnylam Pharmaceuticals, Moderna, BioNTech SE, AstraZeneca PLC, Gilead Sciences, Pfizer, Novartis, and more, each contributing to the competitive landscape.
  • Enabling Technologies: Includes advances in backbone chemistries, conjugate technologies for drug stability and specificity, lipid nanoparticle-based formulations, and the integration of artificial intelligence for drug design.

Nucleic Acid-Based Drugs Market: Key Takeaways

  • Companies leverage advanced molecular engineering to address complex disease targets previously considered unreachable with traditional therapeutics.
  • AI and machine learning now play a central role in candidate screening, optimizing molecule design, and reducing development timelines for new drugs.
  • Collaborative ventures, including consortia and public–private partnerships, accelerate regulatory compliance, standardize practices, and facilitate scaling-up of production.
  • Stakeholders are shifting towards integrated supply chain strategies, blending vertical integration and outsourcing to manage market and regulatory uncertainties.
  • Regional differences in reimbursement policies and healthcare infrastructure drive unique market entry and commercial strategies across the Americas, EMEA, and Asia-Pacific.
  • Intellectual property management and strategic acquisitions are increasingly pivotal for maintaining competitive advantage within the nucleic acid-based therapeutics segment.

Navigating Tariff Impact and Global Supply Chain Adaptation

Recent tariff reforms in the United States have increased import costs for key precursor materials used in nucleic acid drug manufacturing, prompting industry participants to adapt sourcing, negotiate long-term contracts, and build domestic production capabilities. Such shifts affect portfolio prioritization, facility location decisions, and engagement with policymakers to ensure access to essential raw materials. Long-term resilience in supply chain design is now a vital aspect of maintaining market access and sustaining innovation.

Methodology & Data Sources

This analysis integrates both primary and secondary data, including interviews with top biopharma executives, regulatory affairs experts, and manufacturing leaders. Information was corroborated through peer-reviewed sources, regulatory filings, and clinical registries, ensuring robust data triangulation and expert validation at each research stage.

Why This Report Matters

  • Enables senior leaders to identify high-potential market opportunities and anticipate regulatory or supply chain disruptions before they impact business outcomes.
  • Supports precise strategic planning with actionable insights tailored to evolving therapeutic areas and global operational risks.
  • Facilitates cross-functional decision-making by linking technology, regional trends, and competitive benchmarks in a single reference framework.

Conclusion

Nucleic acid-based drugs are entering a critical growth phase, underpinned by innovation and evolving market fundamentals. Forward-thinking strategies, agility, and proactive engagement with both technology and regulatory landscapes are central to capturing value in this dynamic sector.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Advancements in CRISPR-Cas gene editing delivery techniques for precise in vivo therapies
5.2. Development of chemically modified antisense oligonucleotides with improved potency and stability
5.3. Emergence of self-amplifying RNA platforms reducing dosage requirements in vaccine applications
5.4. Integration of artificial intelligence in designing personalized nucleic acid drug sequences for targeted therapies
5.5. Progress in non-viral nanoparticle carriers enabling systemic delivery of siRNA and mRNA therapeutics
5.6. Regulatory frameworks evolving to address safety and efficacy of long-acting nucleic acid modalities
5.7. Collaborations between biotech firms and large pharma accelerating clinical translation of nucleic acid drugs
5.8. Expansion of exosome-based nucleic acid delivery systems for targeted intracellular transport and release
5.9. Adoption of microfluidic manufacturing platforms for scalable production of RNA-based therapeutics
5.10. Advances in allele-specific siRNA design enabling treatment of dominant genetic disorders with high precision
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Nucleic Acid-Based Drugs Market, by Drug Type
8.1. Introduction
8.2. Antisense Oligonucleotides
8.3. DNA/RNA Aptamers
8.4. mRNA-Based Therapeutics
8.5. Nucleoside Analogs
8.6. RNA Interference (RNAi) Therapeutics
8.6.1. MicroRNA (MiRNA)
8.6.2. Short Hairpin RNA (ShRNA)
8.6.3. Short Interfering RNA (SiRNA)
9. Nucleic Acid-Based Drugs Market, by Molecule Type
9.1. Introduction
9.2. Large Molecule
9.3. Small Molecule
10. Nucleic Acid-Based Drugs Market, by Route of Administration
10.1. Introduction
10.2. Inhalation
10.3. Intramuscular
10.4. Intravenous
10.5. Oral
10.6. Subcutaneous
11. Nucleic Acid-Based Drugs Market, by Therapeutic Area
11.1. Introduction
11.2. Cardiovascular Diseases
11.3. Infectious Diseases
11.3.1. Bacterial Infections
11.3.2. Fungal Infections
11.3.3. Viral Infections
11.4. Metabolic Disorders
11.5. Neurological Disorders
11.6. Oncology
11.6.1. Hematologic Malignancies
11.6.2. Solid Tumors
11.7. Rare Diseases
12. Nucleic Acid-Based Drugs Market, by End-User
12.1. Introduction
12.2. Academic & Research Institutes
12.3. Contract Research Organizations
12.4. Hospitals & Clinics
12.5. Pharmaceutical & Biotechnology Companies
13. Americas Nucleic Acid-Based Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Nucleic Acid-Based Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Nucleic Acid-Based Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Alnylam Pharmaceuticals, Inc.
16.3.2. Amgen Inc.
16.3.3. Arcturus Therapeutics Holdings Inc.
16.3.4. Arrowhead Pharmaceuticals, Inc.
16.3.5. AstraZeneca PLC
16.3.6. Beam Therapeutics Inc.
16.3.7. Biogen, Inc.
16.3.8. BioMarin Pharmaceutical Inc.
16.3.9. BioNTech SE
16.3.10. Bluebird Bio, Inc.
16.3.11. CRISPR Therapeutics AG
16.3.12. CureVac N.V.
16.3.13. Dynavax Technologies Corporation
16.3.14. Editas Medicine, Inc.
16.3.15. Eli Lilly and Company
16.3.16. Evotec SE
16.3.17. F. Hoffmann-La Roche Ltd.
16.3.18. Generation Bio Co.
16.3.19. Gilead Sciences, Inc.
16.3.20. GSK PLC
16.3.21. Intellia Therapeutics, Inc.
16.3.22. Ionis Pharmaceuticals, Inc.
16.3.23. Merck & Co., Inc.
16.3.24. Moderna, Inc.
16.3.25. Novartis AG
16.3.26. Novo Nordisk A/S
16.3.27. Orna Therapeutics, Inc.
16.3.28. Pfizer Inc.
16.3.29. ProQR Therapeutics N.V.
16.3.30. Sangamo Therapeutics, Inc.
16.3.31. Sanofi SA
16.3.32. Sarepta Therapeutics, Inc.
16.3.33. Silence Therapeutics PLC
16.3.34. Stoke Therapeutics, Inc.
16.3.35. Takeda Pharmaceutical Company Limited
16.3.36. Vertex Pharmaceuticals Incorporated
16.3.37. Voyager Therapeutics, Inc.
16.3.38. Wave Life Sciences Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. NUCLEIC ACID-BASED DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. NUCLEIC ACID-BASED DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. NUCLEIC ACID-BASED DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. NUCLEIC ACID-BASED DRUGS MARKET: RESEARCHAI
FIGURE 26. NUCLEIC ACID-BASED DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 27. NUCLEIC ACID-BASED DRUGS MARKET: RESEARCHCONTACTS
FIGURE 28. NUCLEIC ACID-BASED DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. NUCLEIC ACID-BASED DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DNA/RNA APTAMERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DNA/RNA APTAMERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MRNA-BASED THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MRNA-BASED THERAPEUTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MICRORNA (MIRNA), BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MICRORNA (MIRNA), BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT INTERFERING RNA (SIRNA), BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT INTERFERING RNA (SIRNA), BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RARE DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 121. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 122. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 123. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 124. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 125. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 126. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 127. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 128. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 129. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 130. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 131. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 132. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 133. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 134. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 135. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 136. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 137. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 138. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 139. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 140. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 141. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 142. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 143. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 144. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 145. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 146. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 147. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 148. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 149. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 150. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 151. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 152. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 204. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 206. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 219. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 220. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 221. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 222. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 223. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 224. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 225. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 226. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 227. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 228. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 229. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 230. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 231. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 232. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 233. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 234. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 235. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 236. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 237. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 238. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 239. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 240. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 241. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 242. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 243. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 244. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 245. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 246. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 247. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 248. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 249. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 250. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 251. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 252. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 253. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 254. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 255. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 256. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 257. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 258. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 259. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 260. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 261. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 262. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 263. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 264. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 267. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 268. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 269. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 270. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 271. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 272. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 273. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 274. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 275. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 276. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 277. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 278. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 279. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 280. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 281. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 282. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 283. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 284. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 285. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 286. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 287. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 288. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 289. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 290. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 291. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 292. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 293. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 294. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 295. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 296. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 297. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 298. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 299. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 300. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 301. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 302. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 303. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 304. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 305. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 306. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 307. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 308. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 309. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Nucleic Acid-Based Drugs market report include:
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Arcturus Therapeutics Holdings Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Beam Therapeutics Inc.
  • Biogen, Inc.
  • BioMarin Pharmaceutical Inc.
  • BioNTech SE
  • Bluebird Bio, Inc.
  • CRISPR Therapeutics AG
  • CureVac N.V.
  • Dynavax Technologies Corporation
  • Editas Medicine, Inc.
  • Eli Lilly and Company
  • Evotec SE
  • F. Hoffmann-La Roche Ltd.
  • Generation Bio Co.
  • Gilead Sciences, Inc.
  • GSK PLC
  • Intellia Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Orna Therapeutics, Inc.
  • Pfizer Inc.
  • ProQR Therapeutics N.V.
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Sarepta Therapeutics, Inc.
  • Silence Therapeutics PLC
  • Stoke Therapeutics, Inc.
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated
  • Voyager Therapeutics, Inc.
  • Wave Life Sciences Ltd.

Table Information

Report AttributeDetails
No. of Pages193
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 37.76 Billion
Forecasted Market Value ( USD ) by 2030 $ 70.95 Billion
Compound Annual Growth Rate13.3%
Regions CoveredGlobal
No. of Companies Mentioned39

Related Topics

Related Reports

Nucleic Acid Drug Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Nucleic Acid Drug Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Primary Ciliary Dyskinesia (PCD) Global Market Report 2025 - Product Image

Primary Ciliary Dyskinesia (PCD) Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Oligonucleotide Therapy Market Report 2025 - Product Image

Oligonucleotide Therapy Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Specialty Pharmaceuticals Market by Drug Type (Biologics, Biosimilars, Small Molecule Drugs), Product Type (Branded, Generics), Route Of Administration, Therapeutic Area, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Specialty Pharmaceuticals Market by Drug Type (Biologics, Biosimilars, Small Molecule Drugs), Product Type (Branded, Generics), Route Of Administration, Therapeutic Area, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Cyclodextrin in Pharma Market by Product Type (Modified, Natural), Route of Administration (Nasal, Ophthalmic, Oral), Application, Therapeutic Area - Global Forecast 2025-2030 - Product Image

Cyclodextrin in Pharma Market by Product Type (Modified, Natural), Route of Administration (Nasal, Ophthalmic, Oral), Application, Therapeutic Area - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.